LENSAR (LNSR) 주식 개요
상용 단계의 의료기기 회사인 렌즈사는 미국, 유럽, 아시아, 한국 및 전 세계에서 백내장 치료와 기존 또는 수술로 유발된 각막 난시 관리를 위한 레이저 시스템을 설계, 개발 및 마케팅하는 데 주력하고 있습니다. 자세히 보기
LNSR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LENSAR, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$5.86 |
| 52주 최고가 | US$13.74 |
| 52주 최저가 | US$5.06 |
| 베타 | 0.84 |
| 1개월 변동 | 12.48% |
| 3개월 변동 | -50.59% |
| 1년 변동 | -56.85% |
| 3년 변동 | 99.32% |
| 5년 변동 | -32.25% |
| IPO 이후 변동 | -34.89% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 04
LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.내러티브 업데이트 • Apr 19
LNSR: Buy Thesis Rebuilds Around Post Deal Selloff And Adoption Reacceleration
Analysts have raised their price targets on LENSAR shares to $10, citing renewed optimism around ALLY System adoption and viewing the post acquisition setback selloff as a second chance for investors. Analyst Commentary Bullish Takeaways Bullish analysts point to a $10 price target as a simple yardstick for how they frame upside potential if ALLY System adoption trends seen before the Alcon deal announcement can be re established.
새로운 내러티브 • Apr 17
Cataract Procedure Bundling Will Pressure Margins Yet Recurring Revenue Should Support Gradual Recovery
Catalysts About LENSAR LENSAR develops and commercializes robotic femtosecond laser systems for cataract surgery, with a focus on its ALLY Robotic Laser Cataract System. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Apr 03
LNSR: Buy Rating Resets Around Post Deal Selloff And Execution Rebuild
Analysts have trimmed their price target for LENSAR to $8.50 from $12.50, reflecting updated views on revenue growth, profitability and a lower future P/E, while also pointing to recent upgrades that highlight renewed interest in the stock following the failed Alcon acquisition. Analyst Commentary Recent Street research has focused on the reset expectations for LENSAR following the failed Alcon transaction, as well as the potential runway for the company’s ALLY System.
새로운 내러티브 • Mar 31
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Catalysts About LENSAR LENSAR develops and commercializes the ALLY Robotic Laser Cataract System for laser assisted cataract surgery. What are the underlying business or industry changes driving this perspective?Recent updates
내러티브 업데이트 • May 04
LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.내러티브 업데이트 • Apr 19
LNSR: Buy Thesis Rebuilds Around Post Deal Selloff And Adoption Reacceleration
Analysts have raised their price targets on LENSAR shares to $10, citing renewed optimism around ALLY System adoption and viewing the post acquisition setback selloff as a second chance for investors. Analyst Commentary Bullish Takeaways Bullish analysts point to a $10 price target as a simple yardstick for how they frame upside potential if ALLY System adoption trends seen before the Alcon deal announcement can be re established.새로운 내러티브 • Apr 17
Cataract Procedure Bundling Will Pressure Margins Yet Recurring Revenue Should Support Gradual Recovery
Catalysts About LENSAR LENSAR develops and commercializes robotic femtosecond laser systems for cataract surgery, with a focus on its ALLY Robotic Laser Cataract System. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Apr 03
LNSR: Buy Rating Resets Around Post Deal Selloff And Execution Rebuild
Analysts have trimmed their price target for LENSAR to $8.50 from $12.50, reflecting updated views on revenue growth, profitability and a lower future P/E, while also pointing to recent upgrades that highlight renewed interest in the stock following the failed Alcon acquisition. Analyst Commentary Recent Street research has focused on the reset expectations for LENSAR following the failed Alcon transaction, as well as the potential runway for the company’s ALLY System.새로운 내러티브 • Mar 31
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Catalysts About LENSAR LENSAR develops and commercializes the ALLY Robotic Laser Cataract System for laser assisted cataract surgery. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 19
LNSR: Buy Rating And Post Deal Reset Will Drive Future Reassessment
Analysts have trimmed their fair value estimate for LENSAR from $15.00 to $12.50, pointing to revised assumptions around discount rates, margins, and future P/E, alongside a BTIG upgrade to Buy that highlights past ALLY System adoption and the recent post acquisition selloff as a potential second chance for investors to reassess the story. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the cut in fair value to $12.50 still sits above the current $10 price target.새로운 내러티브 • May 10
Global System Placements Will Improve Operating Room Efficiency
Strong system placements and contract pipelines in international markets enhance potential for sustained revenue growth and competitive advantage.분석 기사 • Jan 28
Even With A 28% Surge, Cautious Investors Are Not Rewarding LENSAR, Inc.'s (NASDAQ:LNSR) Performance Completely
Despite an already strong run, LENSAR, Inc. ( NASDAQ:LNSR ) shares have been powering on, with a gain of 28% in the...분석 기사 • Dec 24
We're Hopeful That LENSAR (NASDAQ:LNSR) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, LENSAR...분석 기사 • Oct 24
Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
LENSAR, Inc. ( NASDAQ:LNSR ) shareholders would be excited to see that the share price has had a great month, posting a...분석 기사 • Sep 12
LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jul 16
LENSAR, Inc. (NASDAQ:LNSR) Doing What It Can To Lift Shares
With a price-to-sales (or "P/S") ratio of 1.3x LENSAR, Inc. ( NASDAQ:LNSR ) may be sending bullish signals at the...분석 기사 • May 01
Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet
Key Insights LENSAR to hold its Annual General Meeting on 7th of May Salary of US$541.1k is part of CEO Nick Curtis's...분석 기사 • Feb 22
LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story
LENSAR, Inc. ( NASDAQ:LNSR ) shares have continued their recent momentum with a 33% gain in the last month alone...분석 기사 • Jan 24
Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Dec 20
Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right now...분석 기사 • Oct 21
Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Sep 13
Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...분석 기사 • Mar 21
This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts
One thing we could say about the covering analyst on LENSAR, Inc. ( NASDAQ:LNSR ) - they aren't optimistic, having just...분석 기사 • Mar 18
Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Nov 01
Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Aug 08
LENSAR GAAP EPS of -$0.67, revenue of $8M
LENSAR press release (NASDAQ:LNSR): Q2 GAAP EPS of -$0.67. Revenue of $8M (+1.3% Y/Y). Adjusted EBITDA was -$4.3M for the quarter ended June 30, 2022 and -$2.3M for the quarter ended June 30, 2021. As of June 30, 2022, the company had cash and cash equivalents of $25.2M as compared to $31.6M at December 31, 2021. Based on its cash position and operational forecasts, the company believes it has sufficient cash to fund operations into 2024.분석 기사 • Mar 23
LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jul 28
We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...주주 수익률
| LNSR | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | -0.3% | -3.5% | 1.3% |
| 1Y | -56.8% | -21.9% | 27.7% |
수익률 대 산업: LNSR은 지난 1년 동안 -21.9%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: LNSR은 지난 1년 동안 27.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| LNSR volatility | |
|---|---|
| LNSR Average Weekly Movement | 13.0% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
안정적인 주가: LNSR의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: LNSR의 주간 변동성은 지난 1년간 7%에서 13%로 증가했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2004 | 150 | Nick Curtis | www.lensar.com |
상용 단계의 의료기기 회사인 렌즈사는 미국, 유럽, 아시아, 한국 및 전 세계에서 백내장 치료와 기존 또는 수술로 유발된 각막 난시 관리를 위한 레이저 시스템을 설계, 개발 및 마케팅하는 데 주력하고 있습니다. 이 회사는 영상, 시술 계획, 디자인 및 정밀도를 제공하여 외과의가 시각적 결과를 얻을 수 있도록 설계된 다양한 독점 기술을 통합한 LENSAR 레이저 시스템을 제공합니다. 또한 외과의가 단일 수술실에서 멸균 레이저 보조 백내장 수술을 수행할 수 있도록 설계된 소형 백내장 치료 시스템인 ALLY 로봇 백내장 레이저 시스템도 제공합니다.
LENSAR, Inc. 기초 지표 요약
| LNSR 기초 통계 | |
|---|---|
| 시가총액 | US$73.23m |
| 순이익 (TTM) | US$29.40m |
| 매출 (TTM) | US$57.70m |
2.4x
주가수익비율(P/E)1.2x
주가매출비율(P/S)LNSR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| LNSR 손익계산서 (TTM) | |
|---|---|
| 매출 | US$57.70m |
| 매출원가 | US$31.33m |
| 총이익 | US$26.38m |
| 기타 비용 | -US$3.02m |
| 순이익 | US$29.40m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 2.43 |
| 총이익률 | 45.71% |
| 순이익률 | 50.94% |
| 부채/자본 비율 | 0% |
LNSR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/27 14:18 |
| 종가 | 2026/05/27 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
LENSAR, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Michael Gorman | BTIG |
| Frank Takkinen | Lake Street Capital Markets, LLC |
| Richard Newitter | Leerink Partners LLC |